XML 30 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
Earnings (Loss) per Share
12 Months Ended
Dec. 26, 2021
Earnings (Loss) per Share  
Earnings (Loss) per Share

7. Earnings (Loss) per Share

We compute earnings (loss) per share using the two-class method. The two-class method requires an earnings allocation formula that determines earnings (loss) per share for common shareholders and participating security holders according to dividends declared and participating rights in undistributed earnings. The shares of Series B Preferred Stock, which were repurchased by the Company or converted into shares of common stock during the second quarter of 2021, and time-based restricted stock awards are participating securities because holders of such shares have non-forfeitable dividend rights and participate in undistributed earnings with common stock. Under the two-class method, total dividends provided to the holders of participating securities and undistributed earnings allocated to participating securities, are subtracted from net income attributable to the Company in determining net income (loss) attributable to common shareholders.  Additionally, any accretion to the redemption value for the Series B Preferred Stock or cash payments in excess of their respective carrying values upon redemption was treated as a deemed dividend in the two-class earnings per share calculation.

Basic earnings (loss) per common share are computed by dividing net income (loss) attributable to common shareholders by the weighted-average common shares outstanding.  Diluted earnings (loss) per common share are computed by dividing the net income (loss) attributable to common shareholders by the diluted weighted average common shares outstanding. Diluted weighted average common shares outstanding consist of basic weighted average common shares outstanding plus weighted average awards outstanding under our equity compensation plans, which are dilutive securities.

The calculations of basic earnings (loss) per common share and diluted earnings (loss) per common share for the years ended December 26, 2021, December 27, 2020 and December 29, 2019 are as follows (in thousands, except per share data):

2021

2020

    

2019

Basic earnings (loss) per common share

Net income attributable to the Company

$

120,016

$

57,932

$

4,866

Dividends on redemption of Series B Convertible Preferred Stock

(109,852)

Dividends paid to participating securities

(6,091)

(14,059)

(12,499)

Net income attributable to participating securities

 

 

(2,136)

 

Net income (loss) attributable to common shareholders

$

4,073

$

41,737

$

(7,633)

Basic weighted average common shares outstanding

 

35,007

 

32,421

 

31,632

Basic earnings (loss) per common share

$

0.12

$

1.29

$

(0.24)

Diluted earnings (loss) per common share

Net income (loss) attributable to common shareholders

$

4,073

$

41,737

$

(7,633)

Weighted average common shares outstanding

 

35,007

 

32,421

 

31,632

Dilutive effect of outstanding equity awards (a)

 

330

 

296

 

Diluted weighted average common shares outstanding (b)

 

35,337

 

32,717

 

31,632

Diluted earnings (loss) per common share

$

0.12

$

1.28

$

(0.24)

(a)Shares subject to options to purchase common stock with an exercise price greater than the average market price for the year were not included in the computation of diluted earnings per common share because the effect would have been antidilutive. The weighted average number of shares subject to antidilutive options was 100 in 2020 (none in 2021 or 2019, respectively).
(b)The Company had 252.5 shares of Series B Preferred Stock outstanding as of December 27, 2020 and December 29, 2019, respectively (none as of December 26, 2021).  For the fully diluted calculation, the Series B Preferred stock dividends were added back to net income (loss) attributable to common shareholders.  The Company then applied the if-converted method to calculate dilution on the Series B Preferred Stock, which resulted in 5.0 million additional common shares.  This calculation was anti-dilutive for both periods presented and as such was excluded.

See Note 20 for additional information regarding our equity awards, including restricted stock.